Publications by authors named "Nafisah B Atako"
Metastatic and high-risk localized prostate cancer respond to hormone therapy but outcomes vary. Following a pre-specified statistical plan, we used Cox models adjusted for clinical variables to test associations with survival of multi-gene expression-based classifiers from 781 patients randomized to androgen deprivation with or without abiraterone in the STAMPEDE trial. Decipher score was strongly prognostic (p<2×10) and identified clinically-relevant differences in absolute benefit, especially for localized cancers.
View Article and Find Full Text PDFArticle Synopsis
- The STAMPEDE trial investigates high-risk hormone-sensitive prostate cancer by using targeted next-generation sequencing (tNGS) to analyze tumor and germline DNA from patients starting androgen-deprivation therapy.
- In the first stage, tNGS was successfully performed on tumor samples from 185 of 287 patients, revealing significant genomic aberrations linked to the PI3K pathway, with a high prevalence of de novo metastatic prostate cancer.
- The study concludes that genomic profiling is feasible with diagnostic samples and highlights similarities and differences in the genomic landscapes of advanced metastatic prostate cancer, which will aid in developing future biomarker-directed treatments.
Background: Observational data have been conflicted regarding the potential role of HIV antiretroviral therapy (ART) as a causative factor for, or protective factor against, COPD. We therefore aimed to investigate the effect of immediate versus deferred ART on decline in lung function in HIV-positive individuals.
Methods: We did a nested substudy within the randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial at 80 sites in multiple settings in 20 high-income and low-to-middle-income countries.